Paxlovid, the “Tamiflu” of COVID-19, the oral medication shown to reduce hospitalizations, also is known for its “rebound” – a recurrence of COVID-19 a few days after completing the entire course of treatment. The New England Journal of Medicine reports on why – it’s the viral load.
A new paper reports that Paxlovid-resistant Covid has been isolated, calling into question the utility of the drug as well as how it should be used. Is this cause for alarm? Not yet, but it could become just that. A look at viral resistance to drugs.